Pulse on Heart Drugs
Why experts predict volatile years ahead for the global cardiovascular drug market.
The cardiovascular drug market is expected to reach $116.3 billion this year. Current market research from business intelligence firm Piribo states that the global cardiovascular drug market will experience a period of high volatility from 2011 to 2015. The reasons? Key products, including blockbusters Plavix and Lovenox, are facing patent expiration. Plavix is an anti-platelet comarketed by Bristol-Myers Squibb (in the U.S.) and sanofi-aventis (rest of world). Approved in 1997, it is one of the top three best-selling drugs and had total sales of about $5.6 billion in 2008. The Plavix patent expires in 2011. Lovenox, an anticoagulant from sanofi-aventis for the treatment of acute deep vein thrombosis expires in 2012. The drug has consistently brought in on average $2.6 billion a year for sanofi-aventis since 2004, with projected sales of $3.7 billion in 2010.
Meanwhile, the patent expiration of Pfizer's Lipitor in 2011, coupled with other factors, led to its apparent exit from R&D in the cardiovascular market. Those factors included Pfizer's Phase III halting of torcetrapid due to excessive mortality (with an $800 million price tag); and a recognition that the drug blockbuster days are over and the next wave of compounds will be complex to develop, both from a regulatory and clinical standpoint.
Cardiovascular Drugs in Development
However, based on the increase in Type II diabetes and obesity in worldwide populations, the demand for cardiovascular drugs are not going to abate.
In a
For the future, he advised CROs and service providers to be prepared to provide more sophisticated biomarker and imaging studies in Phase I and Phase II to demonstrate that molecular targets are being hit, as well as being able to measure microvascular and potential safety complications.
Articles in this issue
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025